Vaxart (VXRT) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VXRT shares.
View VXRT analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12-month price objectives for Vaxart's shares. Their VXRT share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 462.8% from the stock's current price.
View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts.

Vaxart's stock was trading at $0.9609 at the beginning of 2023. Since then, VXRT stock has decreased by 12.2% and is now trading at $0.8440.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our VXRT earnings forecast.

Vaxart, Inc. (NASDAQ:VXRT) issued its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.15 million.

ETFs with the largest weight of Vaxart (NASDAQ:VXRT) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).

Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.50%), Geode Capital Management LLC (1.96%), State Street Corp (1.96%), Two Sigma Investments LP (0.88%), Two Sigma Advisers LP (0.81%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Armistice Capital, Llc, Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, W Mark Watson and Wouter Latour.
View institutional ownership trends.

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VXRT stock can currently be purchased for approximately $0.84.

Vaxart (NASDAQ:VXRT) has a market capitalization of $114.44 million and generates $697,000.00 in revenue each year. The biotechnology company earns $-107,760,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

The company employs 110 workers across the globe.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The official website for the company is www.vaxart.com. The biotechnology company can be reached via phone at (650) 550-3500, via email at ir@vaxart.com, or via fax at 650-871-8580.